Cerus has been granted a patent for methods and processing sets designed to prepare pathogen-inactivated platelet compositions. The processing set includes containers for combining a pathogen inactivation compound, photochemical inactivation, and a compound adsorption device, ensuring sterile transfer of the treated platelet composition. GlobalData’s report on Cerus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cerus, Automatic disinfection robots was a key innovation area identified from patents. Cerus's grant share as of July 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
Pathogen-inactivated platelet composition preparation methods and sets
The granted patent US12064537B2 outlines a processing set designed for the preparation of a pathogen-inactivated platelet composition. This set includes three primary containers: the first container holds a pathogen inactivation compound (PIC), specifically a psoralen, which is combined with a platelet composition. The second container is coupled to the first and is used for the photochemical inactivation of the platelet composition, which can range in volume from approximately 250 mL to 750 mL. The third container, which contains a compound adsorption device (CAD), is also coupled to the second container, allowing for the sterile transfer of the photochemically inactivated platelet composition. The patent specifies that the third container should have a volume between 1.2 L and 1.6 L or a surface area of 800 cm² to 1200 cm².
Additionally, the processing set may include one or more fourth containers that facilitate the transfer and storage of the pathogen-inactivated platelet composition under sterile conditions. These fourth containers are designed to maintain the composition for at least five days at room temperature, with specific pH requirements after storage. The patent also details various configurations regarding the number of fourth containers, the volume of the platelet composition, and the amount of adsorbent beads in the CAD, ensuring flexibility in the processing set's application. Overall, the claims emphasize the sterile handling and effective storage of pathogen-inactivated platelets, which are crucial for safe transfusion practices.
To know more about GlobalData’s detailed insights on Cerus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
